Brauchen wir beim metastasierten Adenokarzinom der Lunge immer eine EGFR-Mutationsanalyse vor der palliativen Firstline-Therapie? Pro

Schlüsselwörter

Lungenkarzinom - Tyrosinkinase-Inhibitor (TKI) - Epidermaler Wachstumsfaktor Rezeptor (EGFR) - aktivierende Mutation

Keywords

lung cancer - tyrosine kinase inhibitor (TKI) - epidermal growth factor receptor (EGFR) - activating mutation

• Literatur

• 1 Gridelli C et al. An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. J Clin Oncol 2010; 28 Abstract 7508
• 2 Inoue A et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009; 27: 1394-1400
• 3 Oxnard GR et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011; 17: 5530-5537
• 4 Rosell R et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations. J Clin Oncol 2011; 29 Abstract 7503
• 5 Thongprasert S et al. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 2011; 6: 1872-1880